Clinical Commander

Back to dossier
cardio.hypertensive-emergency.post-stroke.v1PRODUCTION
cardio.hypertensive-emergency.post-stroke.v1

Hypertensive emergency in acute ischemic stroke (autoregulation-aware BP target by reperfusion eligibility)

cardiologyacuteadult
Hard-required inputs
0 / 10
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Hypertensive emergency in acute ischemic stroke — cerebral autoregulation impaired; BP target depends on reperfusion eligibility (lytic <185/110 pre-bolus, thrombectomy 140-180 pre-procedure, ineligible permissive >220 or >120). AVOID precipitous drop (penumbral hypoperfusion). Distinguish from ICH (lower target 130-140 per INTERACT-3 PMID 37004949). Route to parent engine for shared HTN-emergency arc + neuro.ischaemic-stroke.v1 for stroke-specific management; this dossier owns reperfusion-band-specific BP titration.

Inputs
4
Actions
0
Advance rule
Set
Advance when

reperfusion eligibility band determined + ICH excluded on CT

Patient inputs (10)

Older patients have rightward-shifted cerebral autoregulation; precipitous BP drop risks penumbral hypoperfusion (AHA/ASA 2024)

Drives lytic window (≤4.5 h alteplase / ≤4.5 h tenecteplase) + thrombectomy window (≤24 h with imaging selection per DAWN/DEFUSE-3); BP target follows reperfusion eligibility

Mandatory before BP lowering — exclude ICH (which has different SBP target per INTERACT-3 PMID 37004949 + AHA/ASA 2022 ICH guideline); confirm ischemic stroke

Identify LVO → drives thrombectomy decision → drives 140-180 SBP band pre-procedure

eGFR drives nicardipine vs nitroprusside selection (cyanide if eGFR <30 + duration); also iodinated contrast risk for CTA

INR + platelets gate alteplase eligibility (INR ≤1.7, platelets ≥100k); also drive ICH-risk stratification post-lytic

Serial CT at 24 h post-lytic (or sooner if neuro decline) — hemorrhagic conversion shifts BP target downward to ICH band

Defines pre-lytic threshold (<185), thrombectomy-window threshold (140-180), and permissive-HTN threshold (>220) per AHA/ASA 2024 PMID 38483443

Pre-lytic threshold <110 (AHA/ASA 2024); component of MAP for reperfusion-window monitoring

Stroke severity drives reperfusion eligibility + BP target band (NIHSS 6-25 with LVO + ASPECTS ≥6 = thrombectomy band)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement
  • informationallife_threateninghemorrhagic_conversion_post_lytic
    New ICH on serial CT (or sooner for neuro decline) within 24 h post-alteplase / post-thrombectomy
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningICH_discovered_on_serial_imaging
    New ICH discovered on serial CT during stroke admission (especially post-lytic or post-thrombectomy or with high-NIHSS)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereBP_overshoot_below_140_in_thrombectomy_candidate
    SBP <140 in patient awaiting or undergoing thrombectomy → penumbral perfusion failure risk
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererecurrent_stroke_despite_anticoagulation
    New stroke in patient already on therapeutic AC for cardioembolic etiology
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

TREATMENTrequiredDrives monitoring threshold
Loading…

Recommended regimen

HTN in acute ischemic stroke — reperfusion-band-specific BP target (lytic <185/110 pre-bolus, <180/105 × 24 h post; thrombectomy 140-180 pre-procedure; permissive >220/120 if not eligible)
axis: htn_post_stroke_reperfusion_band_aware
Selected axis "HTN in acute ischemic stroke — reperfusion-band-specific BP target (lytic <185/110 pre-bolus, <180/105 × 24 h post; thrombectomy 140-180 pre-procedure; permissive >220/120 if not eligible)" by default fallback (first axis)
  • nicardipine
    first line
    DHP_CCB
    5 mg/h IV, titrate by 2.5 mg/h q5-15 min, max 15 mg/h • IV • continuous
    triggers: pre_lytic_BP_lowering, pre_thrombectomy_BP_management, post_lytic_24h_BP_maintenance
    AHA/ASA 2024 PMID 38483443 first-line — predictable titration; no cerebral vasodilation harm; preferred over labetalol for fine titration during reperfusion window
    rxcui 7396
  • labetalol
    second line
    mixed_alpha_beta_blocker
    10-20 mg IV q10 min (max 300 mg cumulative) OR 0.5-2 mg/min infusion • IV • bolus or infusion
    triggers: pre_lytic_rapid_BP_lowering, nicardipine_intolerant, tachycardia_with_HTN
    AHA/ASA 2024 second-line — useful when sympathetic drive high; mixed α/β; no reflex tachycardia; bolus easier than infusion in busy ED
    rxcui 6185
  • clevidipine
    second line
    DHP_CCB_short_acting
    1-2 mg/h IV, titrate q90 sec • IV • continuous
    triggers: need_for_tight_BP_control_post_thrombectomy, volume_overload_concern
    Ultra-short half-life allows minute-to-minute titration during thrombectomy window; lipid emulsion (avoid egg/soy allergy)
    rxcui 233603
  • norepinephrine
    rescue
    vasopressor_alpha_agonist
    0.05-0.5 mcg/kg/min IV, titrate to SBP ≥140 • IV • continuous
    triggers: pre_thrombectomy_SBP_lt_140, precipitous_BP_drop_with_neuro_decline
    BP-TARGET PMID 32569748 + ENCHANTED PMID 27067691 — penumbral perfusion preservation requires SBP ≥140 pre-thrombectomy; vasopressor support if BP drops too far
    rxcui 7512
  • AVOID nitroprusside
    contraindication substitute
    do_not_use
    AVOID • N/A • N/A
    triggers: acute_ischemic_stroke
    Cerebral vasodilation worsens ICP; cyanide risk if eGFR <30 + duration >24 h; AHA/ASA 2024 AVOID in acute stroke
  • AVOID hydralazine
    contraindication substitute
    do_not_use
    AVOID • N/A • N/A
    triggers: acute_ischemic_stroke
    Unpredictable BP drop magnitude + delayed onset → risk of overshoot through penumbral perfusion floor; AHA/ASA 2024 not recommended in acute stroke

outpatient playbook — drug actions (1)

  1. 1. continue secondary stroke prevention bundle
    rxcui 243670
    ASA 81 + atorvastatin 80 + amlodipine + lisinopril (or apixaban if AF) • PO • as scheduled
    trigger: Stable maintenance
    AHA/ASA 2024

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Acute focal neuro deficit (NIHSS ≥1) + SBP ≥185 OR DBP ≥110 — pre-lytic BP lowering window (AHA/ASA 2024 PMID 38483443); CT/MRI confirms acute ischemic stroke (no hemorrhage) + BP elevation requiring management per reperfusion eligibility; Large vessel occlusion (LVO) confirmed on CTA + thrombectomy candidate + BP lowering needed pre-procedure to keep SBP 140-180 (BP-TARGET PMID 32569748).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Hypertensive emergency in acute ischemic stroke (autoregulation-aware BP target by reperfusion eligibility)** (cardio.hypertensive-emergency.post-stroke.v1).
Scope: Hypertensive emergency in acute ischemic stroke — cerebral autoregulation impaired; BP target depends on reperfusion eligibility (lytic <185/110 pre-bolus, thrombectomy 140-180 pre-procedure, ineligible permissive >220 or >120). AVOID precipitous drop (penumbral hypoperfusion). Distinguish from ICH (lower target 130-140 per INTERACT-3 PMID 37004949). Route to parent engine for shared HTN-emergency arc + neuro.ischaemic-stroke.v1 for stroke-specific management; this dossier owns reperfusion-band-specific BP titration.

No severity triggers fired against current inputs.

Plan

Regimen axis: **HTN in acute ischemic stroke — reperfusion-band-specific BP target (lytic <185/110 pre-bolus, <180/105 × 24 h post; thrombectomy 140-180 pre-procedure; permissive >220/120 if not eligible)**.
1. nicardipine 5 mg/h IV, titrate by 2.5 mg/h q5-15 min, max 15 mg/h IV continuous (DHP_CCB, first line) — AHA/ASA 2024 PMID 38483443 first-line — predictable titration; no cerebral vasodilation harm; preferred over labetalol for fine titration during reperfusion window
2. labetalol 10-20 mg IV q10 min (max 300 mg cumulative) OR 0.5-2 mg/min infusion IV bolus or infusion (mixed_alpha_beta_blocker, second line) — AHA/ASA 2024 second-line — useful when sympathetic drive high; mixed α/β; no reflex tachycardia; bolus easier than infusion in busy ED
3. clevidipine 1-2 mg/h IV, titrate q90 sec IV continuous (DHP_CCB_short_acting, second line) — Ultra-short half-life allows minute-to-minute titration during thrombectomy window; lipid emulsion (avoid egg/soy allergy)
4. norepinephrine 0.05-0.5 mcg/kg/min IV, titrate to SBP ≥140 IV continuous (vasopressor_alpha_agonist, rescue) — BP-TARGET PMID 32569748 + ENCHANTED PMID 27067691 — penumbral perfusion preservation requires SBP ≥140 pre-thrombectomy; vasopressor support if BP drops too far
5. AVOID nitroprusside AVOID N/A N/A (do_not_use, contraindication substitute) — Cerebral vasodilation worsens ICP; cyanide risk if eGFR <30 + duration >24 h; AHA/ASA 2024 AVOID in acute stroke
6. AVOID hydralazine AVOID N/A N/A (do_not_use, contraindication substitute) — Unpredictable BP drop magnitude + delayed onset → risk of overshoot through penumbral perfusion floor; AHA/ASA 2024 not recommended in acute stroke

Setting playbook (outpatient) — Long-term cardiology + neurology surveillance — secondary stroke prevention bundle maintenance, BP <130/80 maintained, AC adherence if cardioembolic, lifestyle modification
7. continue secondary stroke prevention bundle ASA 81 + atorvastatin 80 + amlodipine + lisinopril (or apixaban if AF) PO as scheduled — Stable maintenance (AHA/ASA 2024)

Non-pharmacologic actions:
- DASH + lifestyle maintenance
- Smoking cessation maintenance
- Annual neurology + cardiology follow-up

AVOID / contraindication checks:
- Nitroprusside_avoid_in_acute_stroke_ICP_and_cyanide (AHA/ASA 2024 PMID 38483443)
- Hydralazine_unpredictable_avoid_for_acute_stroke (AHA/ASA 2024)
- No_BP_drop_below_SBP_140_pre_thrombectomy (BP TARGET PMID 32569748)
- Permissive_HTN_if_not_reperfusion_eligible_until_SBP_gt_220_or_DBP_gt_120 (AHA/ASA 2024)
- MAP_reduction_capped_at_15pct_first_24h_in_permissive_band (AHA/ASA 2024)

Monitoring

Regimen monitoring:
- arterial line q5-15min BP during reperfusion window (AHA/ASA 2024)
- q15-30min neuro exam first 6h (AHA/ASA 2024)
- NIHSS at baseline 24h and d/c (AHA/ASA 2024)
- serial CT at 24h for hemorrhagic conversion (AHA/ASA 2024)
- GCS trend during titration (BP-TARGET PMID 32569748)
- serial creatinine q4-6h (AHA/ASA 2024)

Setting (outpatient) monitoring:
- Quarterly BP
- Annual lipid + A1c + BMP

Follow-up plan: Transition to oral 4-tier ladder by 24-48 h once stable; outpatient SBP target <130 per SPRINT (PMID 26551272) for secondary stroke prevention; secondary-prevention bundle (statin, antiplatelet, AC if cardioembolic per CHA2DS2-VASc); cardiac rehab if appropriate; BP at home <130/80
- Close-out criterion: oral regimen stable + outpatient stroke follow-up booked + 2nd-prevention bundle established

Monitoring phase: A-line + q5-15 min BP × 24 h post-lytic / post-thrombectomy; q15-30 min neuro exam during first 6 h; serial CT at 24 h to detect hemorrhagic conversion (or sooner if neuro decline); daily BMP for AKI; HD-NIHSS at 24 h

Disposition

Current setting: outpatient — Long-term cardiology + neurology surveillance — secondary stroke prevention bundle maintenance, BP <130/80 maintained, AC adherence if cardioembolic, lifestyle modification

Disposition criteria:
- Long-term continuation; cross-link to cardio.htn.core.v1 + neuro.ischaemic-stroke.v1

Escalation triggers (move to higher acuity):
- BP rebound → return to ED
- Recurrent neuro symptom → urgent stroke eval

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] New ICH on serial CT (or sooner for neuro decline) within 24 h post-alteplase / post-thrombectomy
- [LIFE_THREATENING] New ICH discovered on serial CT during stroke admission (especially post-lytic or post-thrombectomy or with high-NIHSS)
- [SEVERE] SBP <140 in patient awaiting or undergoing thrombectomy → penumbral perfusion failure risk

Citations

- AHA/ASA 2024 Acute Ischemic Stroke Guideline (Greenberg PMID 38483443) + 2025 ACC/AHA HTN Guideline (Whelton) + ESC/ESH 2024 HTN (Mancia PMID 38613493) [PMID:38483443](https://pubmed.ncbi.nlm.nih.gov/38483443/)
- Cited evidence (PMID 27067691) [PMID:27067691](https://pubmed.ncbi.nlm.nih.gov/27067691/)
- Cited evidence (PMID 32569748) [PMID:32569748](https://pubmed.ncbi.nlm.nih.gov/32569748/)
- Cited evidence (PMID 37004949) [PMID:37004949](https://pubmed.ncbi.nlm.nih.gov/37004949/)
- Cited evidence (PMID 23713578) [PMID:23713578](https://pubmed.ncbi.nlm.nih.gov/23713578/)

Last reconciled with current guidelines: 2026-05-15.
References
  • AHA/ASA 2024 Acute Ischemic Stroke Guideline (Greenberg PMID 38483443) + 2025 ACC/AHA HTN Guideline (Whelton) + ESC/ESH 2024 HTN (Mancia PMID 38613493) — PMID:38483443
  • Cited evidence (PMID 27067691) — PMID:27067691
  • Cited evidence (PMID 32569748) — PMID:32569748
  • Cited evidence (PMID 37004949) — PMID:37004949
  • Cited evidence (PMID 23713578) — PMID:23713578